Gyre Therapeutics, Inc. (NASDAQ:GYRE) Given Average Rating of “Hold” by Analysts

Gyre Therapeutics, Inc. (NASDAQ:GYRE) has been given an average recommendation of “Hold” by the five research firms that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have given a buy recommendation to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $17.00.

Several research analysts have commented on the stock. Weiss Ratings reissued a “sell (d)” rating on shares of Gyre Therapeutics in a report on Thursday, January 22nd. Wall Street Zen raised Gyre Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, November 15th. Zacks Research upgraded Gyre Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Friday, November 14th. Finally, Jefferies Financial Group began coverage on Gyre Therapeutics in a report on Friday, October 10th. They issued a “buy” rating and a $16.00 price target on the stock.

Institutional Investors Weigh In On Gyre Therapeutics

Several hedge funds have recently bought and sold shares of the stock. State of Alaska Department of Revenue purchased a new position in Gyre Therapeutics in the 3rd quarter worth approximately $38,000. Bank of America Corp DE grew its position in Gyre Therapeutics by 28.8% in the second quarter. Bank of America Corp DE now owns 6,277 shares of the company’s stock worth $46,000 after acquiring an additional 1,402 shares in the last quarter. JPMorgan Chase & Co. increased its stake in Gyre Therapeutics by 84.6% in the second quarter. JPMorgan Chase & Co. now owns 6,461 shares of the company’s stock valued at $47,000 after acquiring an additional 2,961 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Gyre Therapeutics by 77.8% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,413 shares of the company’s stock valued at $54,000 after acquiring an additional 3,244 shares during the last quarter. Finally, Lazard Asset Management LLC purchased a new stake in Gyre Therapeutics during the third quarter valued at about $111,000. 23.99% of the stock is currently owned by institutional investors.

Gyre Therapeutics Trading Down 1.9%

GYRE stock opened at $7.77 on Thursday. The firm has a 50 day moving average of $7.65 and a 200-day moving average of $7.67. The firm has a market capitalization of $748.48 million, a P/E ratio of 259.09 and a beta of 1.97. Gyre Therapeutics has a 12 month low of $6.11 and a 12 month high of $13.75.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.

Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.